Proprietary AI analyst is now available

Oxford Nanopore Technologies Valuation Multiples

Discover revenue and EBITDA valuation multiples for Oxford Nanopore Technologies and similar public comparables like MicroPort Scientific, UFP Technologies, Heron Neutron Medical, Draegerwerk and more.

Oxford Nanopore Technologies Overview

About Oxford Nanopore Technologies

Oxford Nanopore Technologies PLC makes a novel generation of DNA/RNA sequencing technology that provides rich data and is fast, accessible, and easy to use. The company is predominantly involved in researching, developing, manufacturing, and commercializing a nanopore-based sequencing platform that allows the real-time analysis of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). This enables its customers to perform scientific/biomedical research in a range of areas, including human genetics, cancer research, outbreak surveillance, environmental analysis, pathogens/antimicrobial resistance, microbiome analysis, and crop science. The company's reportable segments are; Life Science Research Tools which generates key revenue, and COVID Testing.


Founded

2005

HQ

United Kingdom

Employees

1.3K

Financials (LTM)

Revenue: $329M
EBITDA: ($99M)

EV

$1B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Oxford Nanopore Technologies Financials

Oxford Nanopore Technologies reported last 12-month revenue of $329M and negative EBITDA of ($99M).

In the same LTM period, Oxford Nanopore Technologies generated $200M in gross profit, ($99M) in EBITDA losses, and had net loss of ($173M).

Revenue (LTM)


Oxford Nanopore Technologies P&L

In the most recent fiscal year, Oxford Nanopore Technologies reported revenue of $301M and EBITDA of ($116M).

Oxford Nanopore Technologies is unprofitable as of last fiscal year, with gross margin of 59%, EBITDA margin of (39%), and net margin of (65%).

See analyst estimates for Oxford Nanopore Technologies
LTMLast FY202320242025202620272028
Revenue$329M$301M$228M$246M$301M
Gross Profit$200M$176M$121M$142M$176M
Gross Margin61%59%53%58%59%
EBITDA($99M)($116M)($142M)($125M)($117M)
EBITDA Margin(30%)(39%)(62%)(51%)(39%)
EBIT Margin(52%)(63%)(99%)(83%)(69%)
Net Profit($173M)($194M)($207M)($196M)($195M)
Net Margin(53%)(65%)(91%)(80%)(65%)

Financial data powered by Morningstar, Inc.

Oxford Nanopore Technologies Stock Performance

Oxford Nanopore Technologies has current market cap of $2B, and enterprise value of $1B.

Market Cap Evolution


Oxford Nanopore Technologies' stock price is $1.81.

Oxford Nanopore Technologies share price decreased by 6.3% in the last 30 days, and by 1.3% in the last year.

Oxford Nanopore Technologies has an EPS (earnings per share) of $-0.20.

See more trading valuation data for Oxford Nanopore Technologies
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$1B$2B-1.4%-6.3%20.1%-1.3%$-0.20

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Oxford Nanopore Technologies Valuation Multiples

Oxford Nanopore Technologies trades at 4.5x EV/Revenue multiple, and (14.8x) EV/EBITDA.

See NTM and 2027E valuation multiples for Oxford Nanopore Technologies

EV / Revenue (LTM)


Oxford Nanopore Technologies Financial Valuation Multiples

As of June 5, 2026, Oxford Nanopore Technologies has market cap of $2B and EV of $1B.

Oxford Nanopore Technologies has a P/E ratio of (10.1x).

LTMLast FY202320242025202620272028
EV/Revenue4.5x4.9x6.5x6.0x4.9x
EV/EBITDA(14.8x)(12.7x)(10.3x)(11.8x)(12.5x)
EV/EBIT(8.7x)(7.8x)(6.5x)(7.2x)(7.0x)
EV/Gross Profit7.3x8.3x12.1x10.4x8.3x
P/E(10.1x)(9.0x)(8.5x)(9.0x)(9.0x)
EV/FCF(13.3x)(11.8x)(6.7x)(6.9x)(9.4x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Oxford Nanopore Technologies Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Oxford Nanopore Technologies Margins & Growth Rates

Oxford Nanopore Technologies grew revenue by 23% but EBITDA decreased by 34% in the last fiscal year.

In the most recent fiscal year, Oxford Nanopore Technologies reported gross margin of 59%, EBITDA margin of (39%), and net margin of (65%).

See estimated margins and future growth rates for Oxford Nanopore Technologies

Oxford Nanopore Technologies Margins

Last FY202420252026202720282029
Gross Margin59%58%59%62%
EBITDA Margin(39%)(51%)(39%)(21%)
EBIT Margin(63%)(83%)(69%)(39%)
Net Margin(65%)(80%)(65%)(40%)
FCF Margin(41%)(87%)(52%)(25%)

Oxford Nanopore Technologies Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth23%8%22%23%
Gross Profit Growth30%16%25%30%
EBITDA Growth(34%)(12%)(6%)(34%)
EBIT Growth(23%)(10%)2%(31%)
Net Profit Growth(25%)(5%)(1%)(25%)
FCF Growth(26%)(4%)(27%)(41%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Oxford Nanopore Technologies Operational KPIs

Oxford Nanopore Technologies' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.3M for the same period.

Oxford Nanopore Technologies' Rule of 40 is 2% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Oxford Nanopore Technologies' Rule of X is 36% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Oxford Nanopore Technologies
LTMLast FY202320242025202620272028
Rule of 40(7%)2%---
Bessemer Rule of X28%36%---
Revenue per Employee-$0.2M---
Opex per Employee-$0.3M---
G&A Expenses to Revenue-84%92%87%84%
R&D Expenses to Revenue39%44%61%54%44%
Opex to Revenue-128%153%141%128%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Oxford Nanopore Technologies Competitors

Oxford Nanopore Technologies competitors include MicroPort Scientific, UFP Technologies, Heron Neutron Medical, Draegerwerk, MicroPort, Embla Medical, Syngene, 4DMedical, Pulse Biosciences and Generate Biomedicines.

Most Oxford Nanopore Technologies public comparables operate across Life Sciences Tools, Medical Devices, BioTech, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
MicroPort Scientific2.3x2.2x16.0x13.4x
UFP Technologies3.1x3.0x15.5x14.9x
Heron Neutron Medical4492.5x-(105.0x)-
Draegerwerk0.4x0.4x3.8x3.7x
MicroPort7.5x7.0x13.8x13.0x
Embla Medical2.5x2.3x12.1x11.6x
Syngene4.4x4.3x17.2x17.0x
4DMedical395.7x280.9x(92.1x)(28.5x)

This data is available for Pro users. Sign up to see all Oxford Nanopore Technologies competitors and their valuation data.

Start Free Trial

Oxford Nanopore Technologies VC Funding History

Before going public, Oxford Nanopore Technologies raised $1B in total equity funding, across 11 rounds.

Last private valuation of Oxford Nanopore Technologies was $3B, after raising $277M in May 2021 from IP Group, M&G Investments, Nikon, and 2 other investors.


Oxford Nanopore Technologies Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
May-21Undisclosed stageIP Group; M&G Investments; Nikon; Temasek Holdings; Wellington Management$277M$3BOxford Nanopore Technologies is a UK-based DNA and RNA sequencing technology company founded in 2005 as a spinout from the University of Oxford. The company develops nanopore-based sensing technology that provides real-time analytics, with applications ranging from hand-held field devices to population-scale platforms used in biomedical research, infectious disease detection, and food and agriculture sectors. The company gained prominence during the COVID-19 pandemic by providing rapid testing technology to Britain's national health service. In May 2021, Oxford Nanopore raised £195 million ($270 million) in equity financing at a post-money valuation of $3.4 billion. The round included investors IP Group (which committed its full pre-emptive allocation of £26 million and acquired a 14.5% undiluted stake), Nikon, Temasek, Wellington Management, M&G Investment, and unnamed existing backers. New investors contributed $174 million of the round while IP Group contributed the remainder. This represented a significant jump from the company's $1.07 billion valuation in October 2020. For the year ended 31 December 2021, Oxford Nanopore reported total revenue of £133.7 million, comprising £127.0 million in Life Science Research Tools (LSRT) revenue and £6.7 million in COVID-19 testing revenue. LSRT revenue grew 94% compared to 2020's £65.5 million, driven by growth across all customer groups. The company provided guidance for full year 2022 LSRT revenue in the range of £145 million to £160 million and full year 2023 LSRT revenue of £190 million to £220 million, reflecting an expected significant decline in COVID-19 sequencing revenue offset by core business growth. Following the May 2021 round, Oxford Nanopore announced a London IPO in September 2021 with a targeted valuation around £2.4 billion ($3.3 billion). The company subsequently went public on the London Stock Exchange in October 2021, issuing 82.4 million shares at £4.25 ($5.81) each, raising $478 million in gross proceeds at a $4.7 billion valuation. Shares surged 45% on the first day of trading under ticker ONT.
Oct-20Series HCasdin Capital; IHC; RPMI Railpen$109M$2BOxford Nanopore Technologies is a UK-based company founded in 2005 as a spin-out from the University of Oxford that develops and commercializes nanopore-based sensing technology for DNA and RNA analysis. The company's products enable rapid, data-rich genetic analysis with the mission to enable analysis of anything, by anyone, anywhere, with applications spanning biomedical research, cancer research, plant and animal analysis, pathogen detection, and environmental monitoring. In October 2020, Oxford Nanopore raised £84.4 million in new capital from existing and new investors including International Holdings Company (IHC) and RPMI Railpen. This round brought the total capital raised in 2020 to £162.1 million, following earlier fundraisings in January and May of £29.3 million and £48.4 million respectively. Following the October 2020 capital raise, IP Group held a 15.0% undiluted beneficial stake in Oxford Nanopore valued at £257.7 million, implying a post-money valuation of approximately £1.72 billion. The company was generating significant revenue momentum, with full-year 2021 revenue of £133.7 million (compared to £113.9 million in 2020), driven primarily by £127 million in Life Science Research Tools revenue and £6.7 million in COVID-19 testing revenue. The company was also providing forward guidance for 2022 LSRT revenue between £145 million to £160 million and 2023 LSRT revenue of £190 million to £220 million, reflecting strong growth expectations. The capital raise supported rapid acceleration of Oxford Nanopore's commercial and manufacturing operations as well as ongoing innovation in nanopore technology, with the company pursuing further regulatory approvals including Emergency Use Authorization in the United States and partnerships in the United Arab Emirates for its diagnostic testing capabilities.
May-20Undisclosed stage-$60M$3BOxford Nanopore Technologies develops nanopore-based sequencing technology for DNA and RNA analysis, offering real-time, scalable solutions from handheld devices to population-scale platforms, used in research, healthcare, epidemiology, and COVID-19 applications like the LamPORE test. On May 26, 2020, the company raised £48.4M ($59.2M) from new and existing investors across EMEA, US, and Asia, adding to £29M raised in Q4 2019, to support innovation and worldwide growth amid the pandemic. This was part of multiple 2020 fundraisings, including January (£29.3M) and October (£84.4M / $111M+), bringing yearly total to £162.1M. A later round (likely the October 2020 $271M equity financing with investors like Temasek, Wellington Management, M&G, Nikon, and IP Group committing $26M) valued the company at about $3.44B, with IP Group holding a 14.5-15% stake worth £257.7M post-October.
Jan-20Secondary - private-$145M$3BOxford Nanopore Technologies develops nanopore-based DNA/RNA sequencing technologies, including portable devices like MinION and scalable PromethION systems for real-time analysis from pocket to population scale. In May 2020, the company raised £195 million at a £2.4 billion valuation, nearly doubling from prior rounds and bringing total capital raised to £808 million. This primary financing round followed a January 2020 transaction where it raised £29.3 million in new capital and facilitated £80.2 million in secondary sales. For the fiscal year 2020, Oxford Nanopore reported revenue of £113.86 million, more than double the 2019 figure, with £65.5 million from life science research tools (LSRT) and £48.3 million from COVID-19 testing via its LamPORE diagnostic, which accounted for 42% of revenue through a one-time UK government purchase. The company's technologies supported COVID-19 research in over 85 countries and are backed by more than 2,100 scientific publications and over 2,000 patents. Gross margins improved to 41.2% in 2020 amid growth in higher-margin consumables.
Oct-18Undisclosed stageAmgen$64M$2BOxford Nanopore Technologies is a UK-based biotechnology company developing proprietary DNA and RNA sequencing technology using nanopores—nano-scale holes made by proteins in a synthetic membrane—combined with electronics to perform direct, real-time sequencing. The platform ranges from pocket-sized devices like the MinION sequencer to high-throughput benchtop machines such as the PromethION, enabling long-read sequencing of DNA and RNA fragments with applications across genomic analysis, disease research, and pathogen detection. In October 2018, Amgen announced an equity investment of £50 million ($66 million) in Oxford Nanopore. The investment was effected through the purchase of ordinary shares at the same price per share as Oxford Nanopore's primary fundraising round announced in March 2018, which valued the company at approximately $2 billion post-money. Amgen's investment was motivated by the company's work through its subsidiary deCODE Genetics, which had used Oxford Nanopore technology to sequence several hundred human genomes and identify new drug targets. The partnership leveraged Oxford Nanopore's long-read sequencing capability to access previously unreachable genome regions and better understand structural variants associated with disease risk. Founded in 2005, Oxford Nanopore had raised over $1.1 billion in total funding by 2021 and subsequently went public on the London Stock Exchange in September 2021 at a $4.7 billion valuation.
Mar-18Undisclosed stageCCB International; GIC; Hostplus$140M$3BOxford Nanopore Technologies, a UK-based company, develops portable, real-time DNA/RNA sequencing technology using nanopores, with flagship products like the MinION device, known for its compact size and ability to sequence entire genomes in real time. The company raised £100 million ($140M) in March 2018 from global investors including GIC (Singapore), CCB International (China), Hostplus (Australia), and existing investors, marking one of its significant fundraising rounds after a €120M raise in 2016. This brought total funding to over £507 million by then. The post-money valuation reached £1.5 billion according to sources covering the round, with IP Group's 18.3% stake valued at £274.1 million, aligning with that figure (undiluted beneficial ownership). Funds were allocated to build a new high-volume manufacturing facility in Oxford, expand commercial operations to over 70 countries, grow the team, and advance R&D for new nanopore devices like PromethION and the forthcoming smartphone sequencer SmidgION. Oxford Nanopore positioned itself as a disruptor in next-generation sequencing, competing with Illumina, PacBio, and others by offering low-cost, long-read, real-time analysis for applications in clinical diagnostics, infectious disease tracking, food/water surveillance, and large-scale genomics. By 2018, thousands of MinION units were in use globally, with improving yields and chemistry driving adoption. The company continued growth, listing on the London Stock Exchange later and reporting recent revenues like £183.2 million in FY24.
Dec-16Undisclosed stageGT Healthcare Capital Partners; IP Group$123M$2BOxford Nanopore Technologies, a UK-based company spun out from the University of Oxford, develops and sells portable DNA/RNA sequencing devices using nanopore technology, including the MinION sequencer for real-time, scalable analysis applicable anywhere. On December 12, 2016, the company raised £100 million ($126 million) in a private placement of ordinary shares, led by GT Healthcare Capital Partners, a pan-Asian fund focused on healthcare investments with reach in China, alongside existing investor Woodford Investment Management and participants including IP Group plc. This brought total funding since 2005 to £351 million. The post-money valuation reached £1.25 billion, implied by IP Group's 19.7% stake following their £14 million participation in the round. Funds were allocated to expand commercial operations globally, particularly in Asia, accelerate nanopore application development, and grow adoption among scientists. GT Healthcare expressed excitement over Oxford Nanopore's revolutionary platform reshaping DNA/single-molecule sequencing, aiming to extend accessibility into emerging markets like Greater China through collaboration. CEO Gordon Sanghera highlighted the active MinION user community demonstrating myriad real-time sequencing possibilities, aligning with the company's goal of enabling analysis of anything by anyone anywhere. IP Group, a key existing investor, continued support, with their total investment in Oxford Nanopore at £246.3 million post-round. No specific revenue, ARR, or EBITDA figures for Oxford Nanopore near the 2016 round were stated in sources using exact required terms. The round positioned the company for inflection in disruptive innovation within next-generation sequencing, competing toward dominance akin to Illumina, amid maturing technology and market saturation challenges noted in analyses.
Jul-15Undisclosed stageIP Group$109M$2BOxford Nanopore Technologies, a UK-based company developing portable DNA/RNA sequencing technology including the MinION device, raised £70 million ($107-109.4 million) in a private financing round around July 2015, backed by IP Group. This funding supported product and commercial development of platforms like MinION, PromethION, and Metrichor, with MinION distributed to over 1,000 scientists in 50 countries by year-end 2015. IP Group's annual results for 2015 highlight this as a key event, noting a £50.4 million increase in fair value of their holding. A December 2016 £100 million ($126-140 million) raise was led by GT Healthcare with IP Group participating via £14 million, resulting in IP's 19.7% stake valued at £246.3 million, implying a £1.25 billion company valuation post-round. Overall, Oxford Nanopore has raised over $1.2 billion across multiple rounds, with later valuations like $6.84 billion in 2021.
Aug-14Undisclosed stageIP Group; Woodford Investment Management$58M$1BOxford Nanopore Technologies is a UK-based company founded in 2005 that develops nanopore-based electronic molecular analysis systems for DNA, RNA, and protein sequencing. The company designs portable and scalable sequencing devices, including the handheld MinION and higher-throughput GridION and PromethION systems, marketed for applications in scientific research, personalized medicine, crop science, security, defense, and environmental analysis. In August 2014, Oxford Nanopore completed a £35 million ($59 million) fundraising round through a private placement of ordinary shares. New investors in this round included The CF Woodford Equity Income Fund managed by Woodford Investment Management, while existing investors and new subscribers from the UK, US, and mainland Europe also participated. IP Group was a key long-standing investor and shareholder throughout this period. The proceeds were allocated to developing the company's commercial and manufacturing infrastructure, scaling production and logistics, expanding customer support and application development functions, and supporting its research and development pipeline of scalable nanopore-sensing products. By 2014, Oxford Nanopore had built a substantial intellectual property portfolio comprising more than 350 patents and patent applications covering various aspects of nanopore sensing technology. The company operated its MinION Access Programme (MAP) to serve early customers and was preparing commercial releases of its GridION and PromethION systems. Prior to the 2014 round, the company had secured significant backing from multiple institutional investors including IP Group and other funds.
Nov-13Secondary - private-$91M-Oxford Nanopore Technologies, a UK-based company developing nanopore-based electronic molecular analysis systems for DNA sequencing and protein analysis, coordinated a secondary placing on 15 November 2013 where other investors acquired Illumina's 13.5% shareholding for £56.4 million. In October 2013, the company raised £40 million through a private placement of ordinary shares, bringing total funding since 2005 to £145 million. Previous rounds included investments from Lansdowne Partners, IP Group, Invesco Perpetual, and Illumina.
Oct-13Undisclosed stageIP Group; Odey Asset Management$64M$849MOxford Nanopore Technologies, founded in 2005 as a spin-out from the University of Oxford, develops nanopore-based electronic molecular analysis systems for real-time DNA and RNA sequencing using portable devices like MinION and higher-throughput platforms. A secondary placing in November 2013 involved the divestment of Illumina's 13.5% stake for £56.4 million to other investors. The company launched the MinION Access Programme in late 2013 to provide early access to its portable sequencing technology. Oxford Nanopore went public on the London Stock Exchange in September 2021 at a $4.7 billion valuation, raising $478 million, with IP Group retaining a significant stake. The firm has secured over $1 billion in prior funding and focuses on R&D, commercialization, and expanding applications in research, diagnostics, and beyond.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Oxford Nanopore Technologies

When was Oxford Nanopore Technologies founded?Oxford Nanopore Technologies was founded in 2005.
Where is Oxford Nanopore Technologies headquartered?Oxford Nanopore Technologies is headquartered in United Kingdom.
How many employees does Oxford Nanopore Technologies have?As of today, Oxford Nanopore Technologies has over 1K employees.
Who is the CEO of Oxford Nanopore Technologies?Oxford Nanopore Technologies' CEO is Gurdial Sanghera.
Is Oxford Nanopore Technologies publicly listed?Yes, Oxford Nanopore Technologies is a public company listed on London Stock Exchange.
What is the stock symbol of Oxford Nanopore Technologies?Oxford Nanopore Technologies trades under ONT ticker.
When did Oxford Nanopore Technologies go public?Oxford Nanopore Technologies went public in 2021.
Who are competitors of Oxford Nanopore Technologies?Oxford Nanopore Technologies main competitors include MicroPort Scientific, UFP Technologies, Heron Neutron Medical, Draegerwerk, MicroPort, Embla Medical, Syngene, 4DMedical, Pulse Biosciences, Generate Biomedicines.
What is the current market cap of Oxford Nanopore Technologies?Oxford Nanopore Technologies' current market cap is $2B.
What is the current revenue of Oxford Nanopore Technologies?Oxford Nanopore Technologies' last 12 months revenue is $329M.
What is the current revenue growth of Oxford Nanopore Technologies?Oxford Nanopore Technologies revenue growth (NTM/LTM) is 23%.
What is the current EV/Revenue multiple of Oxford Nanopore Technologies?Current revenue multiple of Oxford Nanopore Technologies is 4.5x.
Is Oxford Nanopore Technologies profitable?No, Oxford Nanopore Technologies is not profitable.
What is the current EBITDA of Oxford Nanopore Technologies?Oxford Nanopore Technologies has negative EBITDA and is not profitable.
What is Oxford Nanopore Technologies' EBITDA margin?Oxford Nanopore Technologies' last 12 months EBITDA margin is (30%).
What is the current EV/EBITDA multiple of Oxford Nanopore Technologies?Current EBITDA multiple of Oxford Nanopore Technologies is (14.8x).
What is the current FCF of Oxford Nanopore Technologies?Oxford Nanopore Technologies' last 12 months FCF is ($111M).
What is Oxford Nanopore Technologies' FCF margin?Oxford Nanopore Technologies' last 12 months FCF margin is (34%).
What is the current EV/FCF multiple of Oxford Nanopore Technologies?Current FCF multiple of Oxford Nanopore Technologies is (13.3x).
How many companies Oxford Nanopore Technologies has acquired to date?Oxford Nanopore Technologies hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Oxford Nanopore Technologies has invested to date?Oxford Nanopore Technologies hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Oxford Nanopore Technologies

Lists including Oxford Nanopore Technologies

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial